MedImmune
 MedImmune LLC headquartered in Gaithersburg Maryland became a wholly owned subsidiary of AstraZeneca in 2007. Since being acquired MedImmune has remained a Maryland-based biotechnology development enterprise. It produces Synagis a drug for the prevention of respiratory infections in infants which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005 and FluMist a nasal spray influenza vaccine introduced in 2004.